The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial
Abstract
BACKGROUND: Whether surgical axillary staging as part of breast-conserving therapy can be omitted without compromising survival has remained unclear. METHODS: In this prospective, randomized, noninferiority trial, we investigated the omission of axillary surgery as compared with sentinel-lymph-node biopsy in patients with clinically node-negative invasive breast cancer staged as T1 or T2 (tumor size, ≤5 cm) who were scheduled to undergo breast-conserving surgery. We report here the per-protocol analysis of invasive disease-free survival (the primary efficacy outcome). To show the noninferiority of the omission of axillary surgery, the 5-year invasive disease-free survival rate had to be at least 85%, and the upper limit of the confidence interval for the hazard ratio for invasive disease or death had to be below 1.271. RESULTS: A total of 5502 eligible patients (90% with clinical T1 cancer and 79% with pathological T1 cancer) underwent randomization in a 1:4 ratio. The per-protocol population included 4858 patients; 962 were assigned to undergo treatment without axillary surgery (the surgery-omission group), and 3896 to undergo sentinel-lymph-node biopsy (the surgery group). The median follow-up was 73.6 months. The estimated 5-year invasive disease-free survival rate was 91.9% (95% confidence interval [CI], 89.9 to 93.5) among patients in the surgery-omission group and 91.7% (95% CI, 90.8 to 92.6) among patients in the surgery group, with a hazard ratio of 0.91 (95% CI, 0.73 to 1.14), which was below the prespecified noninferiority margin. The analysis of the first primary-outcome events (occurrence or recurrence of invasive disease or death from any cause), which occurred in a total of 525 patients (10.8%), showed apparent differences between the surgery-omission group and the surgery group in the incidence of axillary recurrence (1.0% vs. 0.3%) and death (1.4% vs. 2.4%). The safety analysis indicates that patients in the surgery-omission group had a lower incidence of lymphedema, greater arm mobility, and less pain with movement of the arm or shoulder than patients who underwent sentinel-lymph-node biopsy. CONCLUSIONS: In this trial involving patients with clinically node-negative, T1 or T2 invasive breast cancer (90% with clinical T1 cancer and 79% with pathological T1 cancer), omission of surgical axillary staging was noninferior to sentinel-lymph-node biopsy after a median follow-up of 6 years. (Funded by the German Cancer Aid; INSEMA ClinicalTrials.gov number, NCT02466737.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt303 · Cited by 3,746
Self-citationGiuliano, A. E. (2011) · JAMA · doi:10.1001/jama.2011.90 · Cited by 2,942
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804710 · Cited by 2,397
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Lyman, G. H., Giuliano, A. E., Somerfield, M. R., Benson, A. B., Bodurka, D. C., Burstein, H. J., Cochran, A. J., Cody, H. S., Edge, S. B., Galper, S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.001 · Cited by 1,887
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Pan, H., Gray, R., Braybrooke, J., Davies, C., Taylor, C., McGale, P., Peto, R., Pritchard, K. I., Bergh, J., Dowsett, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701830 · Cited by 1,822
Fisher, B., Jeong, J.-H., Anderson, S., Bryant, J., Fisher, E. R., & Wolmark, N. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020128 · Cited by 1,400
Hughes, K. S., Schnaper, L. A., Bellon, J. R., Cirrincione, C. T., Berry, D. A., McCormick, B., Muss, H. B., Smith, B. L., Hudis, C. A., Winer, E. P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2615 · Cited by 1,310
Giuliano, A. E., McCall, L., Beitsch, P., Whitworth, P. W., Blumencranz, P., Leitch, A. M., Saha, S., Hunt, K. K., Morrow, M., & Ballman, K. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181f08f32 · Cited by 1,263
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
Kalinsky, K., Barlow, W. E., Gralow, J. R., Meric-Bernstam, F., Albain, K. S., Hayes, D. F., Lin, N. U., Perez, E. A., Goldstein, L. J., Chia, S. K. L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108873 · Cited by 870
Hudis, C. A., Barlow, W. E., Costantino, J. P., Gray, R. J., Pritchard, K. I., Chapman, J.-A. W., Sparano, J. A., Hunsberger, S., Enos, R. A., Gelber, R. D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3523 · Cited by 864
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Tolaney, S. M., Barry, W. T., Dang, C. T., Yardley, D. A., Moy, B., Marcom, P. K., Albain, K. S., Rugo, H. S., Ellis, M., Shapira, I., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406281 · Cited by 753
Per-Protocol Analyses of Pragmatic Trials
Hernán, M. A., & Robins, J. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmsm1605385 · Cited by 660
Gentilini, O. D., Botteri, E., Sangalli, C., Galimberti, V., Porpiglia, M., Agresti, R., Luini, A., Viale, G., Cassano, E., Peradze, N., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.3759 · Cited by 568
Cm, R., Zahrieh, D., Forbes, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5784 · Cited by 408
Quantification of the completeness of follow-up
Clark, T. G., Altman, D. G., & Stavola, B. L. D. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08272-7 · Cited by 406
Radiation Field Design in the ACOSOG Z0011 (Alliance) Trial
Jagsi, R., Chadha, M., Moni, J., Ballman, K. V., Laurie, F., Buchholz, T. A., Giuliano, A. E., & Haffty, B. G. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.5838 · Cited by 393
Brackstone, M., Baldassarre, F. G., Perera, F. E., Cil, T., Chavez Mac Gregor, M., Dayes, I. S., Engel, J., Horton, J. K., King, T. A., Kornecki, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00934 · Cited by 271
van Roozendaal, L. M., Vane, M. L. G., van Dalen, T., van der Hage, J. A., Strobbe, L. J. A., Boersma, L. J., Linn, S. C., Lobbes, M. B. I., Poortmans, P. M. P., Tjan-Heijnen, V. C. G., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3443-x · Cited by 188
Shaitelman, S. F., Anderson, B. M., Arthur, D. W., Bazan, J. G., Bellon, J. R., Bradfield, L., Coles, C. E., Gerber, N. K., Kathpal, M., Kim, L., et al. (2024) · Practical Radiation Oncology · doi:10.1016/j.prro.2023.11.001 · Cited by 187
Taylor, C., Dodwell, D., McGale, P., Hills, R. K., Berry, R., Bradley, R., Braybrooke, J., Clarke, M., Gray, R., Holt, F., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01082-6 · Cited by 168
Self-citationAxillary Dissection Versus No Axillary Dissection in Older Patients With T1N0 Breast Cancer
Martelli, G., Boracchi, P., Ardoino, I., Lozza, L., Böhm, S., Vetrella, G., & Agresti, R. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e31827660a8 · Cited by 152
Reimer, T., Stachs, A., Veselinovic, K., Polata, S., Müller, T. M., Kühn, T., Heil, J., Ataseven, B., Reitsamer, R., Hildebrandt, G., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101756 · Cited by 100
Self-citationAgresti, R., Martelli, G., Sandri, M. F., Tagliabue, E., Carcangiu, M. L., Maugeri, I., Pellitteri, C., Ferraris, C., Capri, G., Moliterni, A., et al. (2013) · Cancer · doi:10.1002/cncr.28499 · Cited by 90
Jung, J. G., Ahn, S. H., Lee, S., Kim, E., Ryu, J. M., Park, S., Lim, W., Jung, Y. S., Chung, I. Y., Jeong, J., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09273-1 · Cited by 86
Reimer, T., Hartmann, S., Stachs, A., & Gerber, B. (2014) · Breast Care · doi:10.1159/000360411 · Cited by 83
Self-citationde Boniface, J., Appelgren, M., Szulkin, R., Alkner, S., Andersson, Y., Bergkvist, L., Frisell, J., Gentilini, O., Kontos, M., Kühn, T., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00350-4 · Cited by 39
Self-citationStachs, A., Thi, A. T.-H., Dieterich, M., Stubert, J., Hartmann, S., Glass, Ä., Reimer, T., & Gerber, B. (2015) · Ultrasound International Open · doi:10.1055/s-0035-1555872 · Cited by 38
Self-citationHsieh, F. Y. (1987) · Statistics in Medicine · doi:10.1002/sim.4780060506 · Cited by 17
Metadata
- Authors
- Reimer, T., Stachs, A., Veselinovic, K., Kühn, T., Heil, J., Polata, S., Marmé, F., Müller, T., Hildebrandt, G., Krug, D., Ataseven, B., Reitsamer, R., Ruth, S., Denkert, C., Bekes, I., Zahm, D.-M., Thill, M., Golatta, M., Holtschmidt, J., Knauer, M., Nekljudova, V., Loibl, S., & Gerber, B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-03-13
- Volume
- 392
- Issue
- 11
- Pages
- 1051-1064
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4405320092
- Cited by
- 313
- References
- 30
- FWCI
- 47.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.